ENTITY
CanSino Biologics

CanSino Biologics (6185 HK)

236
Analysis
Health Care • China
CanSino Biologics is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of innovative vaccine products for human use, primarily focusing on infectious diseases. Its product portfolio includes vaccines for meningitis, pneumonia, pertussis, diphtheria, tetanus, COVID-19, tuberculosis, shingles, and Ebola virus disease. The company was founded in 2009 and is headquartered in Tianjin, China.
more
•02 Jan 2024 07:00

A-H Premium Weekly (Dec 29th): China Tourism, ZTE, Datang Intl, First Tractor, Hua Hong Semi

We analyzed A-H premium changes in the past week and highlighted A-H premium changes for China Tourism, ZTE, Datang Intl, First Tractor, Hua Hong...

Logo
636 Views
Share
•03 Dec 2023 10:10

A-H Premium Weekly (Dec 1st): CMB, Ping An Insurance, Beigene, Ganfeng Lithium

We analyzed A-H premium changes in the past week and highlight A-H premium changes for CMB, Ping An Insurance, Beigene, Ganfeng Lithium.

Logo
727 Views
Share
•12 Nov 2023 10:10

Hong Kong Connect Flows (Nov 10th): Tencent, China Mobile, CNOOC

We analyzed southbound Hong Kong connect flows in the past week and highlight flows for Tencent, China Mobile and CNOOC.

Logo
590 Views
Share
•07 Nov 2023 08:55

CanSino Biologics (6185.HK/688185.CH) 23Q3 - Some Positive Business Progress Worth the Attention

CanSino’s performance/valuation is at low point, but MCV4's sales exceeded expectation.On 2023 low base, growth in 2024 is worth looking forward...

Logo
545 Views
Share
•05 Nov 2023 10:10

Hong Kong Connect Flows (Nov 3rd): Li Ning, SMIC, Xiaomi

We analyzed southbound Hong Kong connect flows in the past week and highlight flows for Li Ning, Semiconductor Manufacturing International, Xiaomi,...

Logo
841 Views
Share
x